Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease is the leading global health concern and responsible for more deaths worldwide than any other type of disorder. Atherosclerosis is a chronic inflammatory disease in the arterial wall, which underpins several types of cardiovascular disease. It has emerged that a strong relationship exists between alterations in amino acid (AA) metabolism and the development of atherosclerosis. Recent studies have reported positive correlations between levels of branched-chain amino acids (BCAAs) such as leucine, valine, and isoleucine in plasma and the occurrence of metabolic disturbances. Elevated serum levels of BCAAs indicate a high cardiometabolic risk. Thus, BCAAs may also impact atherosclerosis prevention and offer a novel therapeutic strategy for specific individuals at risk of coronary events. The metabolism of AAs, such as L-arginine, homoarginine, and L-tryptophan, is recognized as a critical regulator of vascular homeostasis. Dietary intake of homoarginine, taurine, and glycine can improve atherosclerosis by endothelium remodeling. Available data also suggest that the regulation of AA metabolism by indoleamine 2,3-dioxygenase (IDO) and arginases 1 and 2 are mediated through various immunological signals and that immunosuppressive AA metabolizing enzymes are promising therapeutic targets against atherosclerosis. Further clinical studies and basic studies that make use of animal models are required. Here we review recent data examining links between AA metabolism and the development of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596 · cited 2×
“of such conditions are increasing worldwide, mainly due to population growth and poor lifestyle choices (1, 2).”
BackgroundCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 1×
“Leu stimulates myofibrillar protein synthesis (69, 70).”
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 1×
“This observation suggests that neutrophils can deprive their environment of Arg, which may affect surrounding cells (259).”
BackgroundSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Vascular smooth muscle cells in atherosclerosis
Basatemur, G. L., Jørgensen, H. F., Clarke, M. C. H., Bennett, M. R., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0227-9 · Cited by 1,099
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037 · cited 1×
“For example, IDO has been shown to promote infection by reducing host protective immunity (296).”
BackgroundWang (2012) · doi:10.1161/circresaha.111.261388 · Cited by 957 · cited 1×
“In humans, aging is an independent risk factor for atherosclerosis development (145); elderly patients with CVDs exhibit flow-mediated dilation of the brachial artery.”
BackgroundQuinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 4×
“Zhang et al. found that the downstream metabolite, HAA lowers plasma lipids (including cholesterol and triglycerides) and decreases atherosclerosis in hypercholesterolemic mice (111).”
BackgroundInfluentialCompartmentalization of Mammalian Folate-Mediated One-Carbon Metabolism
Tibbetts, A. S., & Appling, D. R. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104810 · Cited by 692 · cited 1×
“DMG is metabolized to sarcosine, providing a substrate for the synthesis of 5,10-methylenetetrahydrofolate (251).”
BackgroundAlmost all about citrulline in mammals
Curis, E., Nicolis, I., Moinard, C., Osowska, S., Zerrouk, N., Bénazeth, S., & Cynober, L. (2005) · Amino Acids · doi:10.1007/s00726-005-0235-4 · Cited by 571
Yurdagul, A., Subramanian, M., Wang, X., Crown, S. B., Ilkayeva, O. R., Darville, L., Kolluru, G. K., Rymond, C. C., Gerlach, B. D., Zheng, Z., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.001 · Cited by 525 · cited 1×
“Such inflammation transforms stable atherosclerotic plaques into unstable forms that can rupture and cause embolization (132).”
BackgroundTryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519 · cited 1×
“Once absorbed through the intestine into theportal blood, 85–90% of Trp is transported in the plasma bound to serum albumin, while only 10– 15% of the total plasma Trp is in the free form (99).”
BackgroundMacrophage plasticity in experimental atherosclerosis
Khallou-Laschet, J., Varthaman, A., Fornasa, G., Compain, C., Gaston, A.-T., Clement, M., Dussiot, M., Levillain, O., Graff-Dubois, S., Nicoletti, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008852 · Cited by 517 · cited 3×
“The M1 macrophages that trigger plaque destabilization and promote thrombus formation are localized in the plaque lipid core in humans but are distributed across the lesion in advanced murine plaques (275, 276).”
BackgroundRecent advances in arginine metabolism: roles and regulation of the arginases
Morris Jr, S. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00278.x · Cited by 485 · cited 1×
“Macrophage ARG1 may slow down the progression of atherosclerotic plaques (306).”
BackgroundSuppression of T-cell functions by human granulocyte arginase
Munder, M. (2006) · Blood · doi:10.1182/blood-2006-11-010389 · Cited by 417
Shimomura, Y., Murakami, T., Nakai, N., Nagasaki, M., & Harris, R. A. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.6.1583s · Cited by 405 · cited 1×
“The BCAAs constitute nearly 40% of all the AAs in the body (67).”
BackgroundChinetti-Gbaguidi, G., Baron, M., Bouhlel, M. A., Vanhoutte, J., Copin, C., Sebti, Y., Derudas, B., Mayi, T., Bories, G., Tailleux, A., et al. (2011) · Circulation Research · doi:10.1161/circresaha.110.233775 · Cited by 387 · cited 2×
“The M1 macrophages that trigger plaque destabilization and promote thrombus formation are localized in the plaque lipid core in humans but are distributed across the lesion in advanced murine plaques (275, 276).”
BackgroundYang, Z., & Ming, X.-F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00533 · Cited by 290 · cited 1×
“Elevated activity of ARG isoforms in the endothelium diminishes the vasoprotective role of NO (301), whereas these two isoforms have opposite roles in macrophages (302).”
BackgroundBöger, R. H., Bode-Böger, S. M., Mügge, A., Kienke, S., Brandes, R., Dwenger, A., & Frölich, J. C. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05582-h · Cited by 252
Nitric oxide, a protective molecule in the cardiovascular system
Lei, J., Vodovotz, Y., Tzeng, E., & Billiar, T. R. (2013) · Nitric Oxide · doi:10.1016/j.niox.2013.09.004 · Cited by 184 · cited 1×
“These mechanical stimuli compromise the integrity of the endothelial barrier by activating signaling pathways that reduce the levels of NO (thereby inhibiting the migration and survival of endothelial cells) (13), and superoxide dismutase (SOD) (thereby increasing cellular oxidative stress) (14), which leads to the ac…”
BackgroundMetabolic fate of leucine: a significant sterol precursor in adipose tissue and muscle
Rosenthal, J., Angel, A., & Farkas, J. (1974) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1974.226.2.411 · Cited by 134
Yun, T. J., Lee, J. S., Machmach, K., Shim, D., Choi, J., Wi, Y. J., Jang, H. S., Jung, I.-H., Kim, K., Yoon, W. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.010 · Cited by 116
LXRα Regulates Macrophage Arginase 1 Through PU.1 and Interferon Regulatory Factor 8
Pourcet, B., Feig, J. E., Vengrenyuk, Y., Hobbs, A. J., Kepka-Lenhart, D., Garabedian, M. J., Morris, S. M., Fisher, E. A., & Pineda-Torra, I. (2011) · Circulation Research · doi:10.1161/circresaha.111.241810 · Cited by 97
Cited by
Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes
Gusev, E., & Sarapultsev, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097910 · Cited by 312
Wang, W.-L., Shih, Y.-T., Wei, S.-Y., & Chiu, J.-J. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01177-z · Cited by 50
“4) [19, 113, 114].”
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Machine learning approaches for biomarker discovery to predict large-artery atherosclerosis
Sun, T.-H., Wang, C.-C., Wu, Y.-L., Hsu, K.-C., & Lee, T.-H. (2023) · Scientific Reports · doi:10.1038/s41598-023-42338-0 · Cited by 32
“Moreover, amino acid metabolism has strong relationships with several types of cardiovascular disease 63 .”
BackgroundNitric Oxide as a Determinant of Human Longevity and Health Span
Poeggeler, B., Singh, K. S., Sambamurti, K., & Pappolla, M. A. (2023) · doi:10.20944/preprints202309.0213.v1 · Cited by 20
Metadata
- Authors
- Zaric, B. L., Radovanovic, J. N., Gluvic, Z., Stewart, A. J., Essack, M., Motwalli, O., Gojobori, T., & Isenovic, E. R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-28
- Volume
- 11
- Pages
- 551758-551758
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3090138050
- Cited by
- 91
- References
- 30
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.